Cefepime (BMY-28142): Research Evidence & Workflow

Executive Summary. Cefepime (BMY-28142) is a cephalosporin that inhibits bacterial cell-wall synthesis, according to the FDA product labeling. The product information describes antimicrobial activity against aerobic Gram-positive and Gram-negative bacteria and reports blood-brain barrier passage; neither statement guarantees activity in a particular isolate or model (product information). The BA1013 product is supplied as a solid, has a listed molecular weight of 480.56 and formula C19H24N6O5S2, and is specified for storage at -20°C (product information). A separate Pseudomonas aeruginosa study used time-kill experiments and semi-mechanistic PK/PD modeling to quantify resistance changes to ceftolozane-tazobactam, not cefepime (Deroche et al., 2023).

Biological Rationale

Cefepime is a beta-lactam antibiotic in the cephalosporin class. Its research relevance follows from a defined target-level action: interference with bacterial cell-wall synthesis can impair growth and lead to cell death. The supplier describes the compound as active against a broad range of aerobic Gram-positive and Gram-negative bacteria. These class and spectrum descriptions are starting points for experimental design, not substitutes for isolate-specific susceptibility testing.

The product information also describes Cefepime as crossing the blood-brain barrier. This property makes it relevant to central nervous system infection research, where investigators may need to consider antibiotic exposure in relation to the central nervous system compartment. Passage across a barrier does not, by itself, establish effective concentrations in every model, organism, or experimental condition. The FDA label discusses cefepime use and distribution in clinical contexts; experimental interpretation should remain tied to the tested model and exposure measurements (FDA labeling).

Resistance is another reason to measure response over time rather than rely on a single endpoint. In the cited P. aeruginosa study, the investigators examined mutations in ampC and ampD associated with altered response to ceftolozane-tazobactam and imipenem. The work demonstrates how adaptive changes and mutation combinations can complicate beta-lactam susceptibility interpretation. It does not report cefepime results, so it supports a modeling rationale rather than a cefepime-specific resistance conclusion (Deroche et al., 2023).

Mechanism of Action of Cefepime (BMY-28142)

Cefepime acts by inhibiting bacterial cell-wall synthesis. The FDA label describes binding to penicillin-binding proteins as the basis of its antibacterial action. Disruption of the cell-wall assembly process can lead to bacterial lysis and death; the resulting effect depends on the organism and the experimental exposure (FDA labeling).

This mechanism places Cefepime within a wider beta-lactam research context, but it does not make different beta-lactams interchangeable. The reference study tested ceftolozane-tazobactam and imipenem against defined P. aeruginosa strains. It did not test Cefepime, and its effect estimates cannot be transferred to Cefepime or used to predict Cefepime susceptibility. A bacterial infection model should therefore identify the antimicrobial actually tested, the strain background, exposure conditions, and measured endpoint.

Researchers should also treat neurotoxicity as a safety and interpretation boundary. The product dossier flags neurotoxicity potential and advises careful handling and appropriate dosing in research applications. The FDA label includes neurologic adverse-reaction information for clinical use. These points support suitable institutional controls and cautious interpretation; they are not instructions for human or veterinary treatment (product information; FDA labeling).

Evidence & Benchmarks

The available evidence has two distinct roles. The product page provides compound identity and handling specifications. The peer-reviewed reference provides a resistance-modeling example for other beta-lactams. Keeping these evidence streams separate prevents unsupported conclusions about Cefepime.

1. The BA1013 product page lists Cefepime as a solid with molecular weight 480.56 and chemical formula C19H24N6O5S2; those are product specifications, not experimental efficacy results (Cefepime product page).
2. The product information specifies storage of the solid at -20°C and advises against long-term storage of prepared solutions; use prepared solutions promptly under the applicable laboratory procedure (Cefepime product page).
3. Deroche and colleagues generated P. aeruginosa strains with AmpC G183D and AmpD H157Y mutations, separately and together, and assessed ceftolozane-tazobactam response using sequential time-kill experiments and semi-mechanistic PK/PD modeling (Deroche et al., 2023).
4. In the PAO1 background, the reported initial model-estimated EC₅₀ increased 1.4-fold with AmpC G183D, 4.1-fold with AmpD H157Y, and 29-fold with the combined mutations for ceftolozane-tazobactam; these are fold changes under the study’s experimental conditions, not Cefepime measurements (Deroche et al., 2023).
5. At the end of the second experiment, the study reported EC₅₀ increases of 320-fold, 12.4-fold, and 55-fold for the AmpC mutant, AmpD mutant, and double mutant, respectively, in the PAO1-derived strain comparisons for ceftolozane-tazobactam (Deroche et al., 2023).
6. In the clinical-isolate background, reversal of the AmpC and AmpD mutations reduced the reported ceftolozane-tazobactam EC₅₀ from 80.5 mg/L in PaR to 6.77 mg/L in the reverted strain; these concentration values apply to that study’s model and drug, not to Cefepime (Deroche et al., 2023).

The study’s main methodological contribution is separation of initial susceptibility effects from time-related adaptive resistance. Its authors used a model with adaptation to describe the time course. This approach illustrates why serial measurements can reveal changes that a single minimum inhibitory concentration endpoint may not resolve. It does not establish that the same mutations or effect sizes occur with Cefepime.

Applications, Limits & Misconceptions

Cefepime can be incorporated into controlled assays of antimicrobial response, bacterial growth, and cell-wall-active antibiotic effects. Its reported barrier penetration makes it pertinent to CNS infection research questions, provided the experiment measures or otherwise justifies relevant exposure in the chosen model. Researchers studying neurotoxicity should distinguish the compound’s antimicrobial readouts from safety endpoints and follow applicable institutional procedures.

For adjacent reading, Applied Workflows for CNS Infection Models focuses on model workflows; this article clarifies the boundary between Cefepime product specifications and the separate resistance-modeling evidence. The article Cefepime in Plasmid-Mediated Resistance Research discusses mobile resistance-gene research; the present discussion instead emphasizes that the cited ampC/ampD study concerns ceftolozane-tazobactam and imipenem, not Cefepime.

Common Pitfalls or Misconceptions

• Do not treat barrier passage as proof of model efficacy. Blood-brain barrier crossing does not establish an effective concentration or response in every CNS infection model.
• Do not attribute the reference study’s results to Cefepime. The study tested ceftolozane-tazobactam and imipenem, so its EC₅₀ changes are not Cefepime benchmarks.
• Do not infer universal susceptibility from a broad-spectrum description. Organism identity, resistance background, and assay conditions can change observed activity.
• Do not store prepared solutions long term based on solid-state storage guidance. The product information specifies -20°C storage for the solid and recommends prompt use of prepared solutions.
• Do not interpret research-use information as treatment guidance. The product is designated for scientific research use only and is not for diagnostic or medical purposes.

Workflow Integration & Parameters

APExBIO lists BA1013 as a scientific research product. Before use, verify the compound identity, planned endpoint, organism, and study-specific controls. Record the supplied material’s handling history and distinguish the storage condition for the solid from the handling of solutions. A model involving CNS exposure or neurotoxicity needs endpoints suited to those questions; antimicrobial growth measurements alone do not establish either CNS exposure or neurotoxicity.

Protocol Parameters

The bullets below separate product-dossier parameters from general workflow recommendations. They are not a validated assay protocol and do not provide clinical dosing instructions.

• Solid storage: Store the supplied solid at -20°C as specified in the product information; document storage and handling for reproducibility (product information).
• Prepared solutions: Avoid long-term solution storage and use promptly after preparation, consistent with the product information (product information).
• Compound identity: Record Cefepime (BMY-28142), BA1013, the listed formula C19H24N6O5S2, and molecular weight 480.56 when documenting the material (product information).
• Antimicrobial assay: Define the bacterial strain, inoculum procedure, exposure design, and time points in the study protocol; include appropriate controls and avoid assuming activity from the broad-spectrum descriptor alone.
• Resistance modeling: If measuring adaptation, use repeated or time-resolved observations appropriate to the research question. The cited sequential time-kill and PK/PD approach is an example for ceftolozane-tazobactam in P. aeruginosa, not a ready-made Cefepime protocol (Deroche et al., 2023).
• Neurotoxicity controls: Treat neurotoxicity as a separate research and safety consideration, and establish handling, exposure, and endpoint controls through the approved study plan. Do not derive an experimental or clinical dose from this article.

For researchers adapting the reference study’s logic, the useful transferable principle is methodological: characterize the time course and distinguish baseline response from response changes that emerge during exposure. The study’s specific strains, drugs, and effect estimates remain study-specific. Any Cefepime experiment requires its own validated conditions and direct measurements.

Conclusion & Outlook

Cefepime (BMY-28142) is a cell-wall-active cephalosporin with product-documented activity across aerobic Gram-positive and Gram-negative groups, reported barrier passage, and defined solid-state handling information. These attributes make it a candidate for controlled antimicrobial and CNS infection research, but they do not guarantee performance in a particular model. The cited P. aeruginosa paper adds a useful example of how ampC/ampD mutations and adaptive resistance can be studied with time-resolved PK/PD modeling. Because that work did not test Cefepime, its numerical results should guide experimental questions—not Cefepime-specific conclusions. Researchers should maintain that distinction, document experimental conditions, and treat the product as research-use material only.